News
The day at a glance · 4 min read
Mood · Mixed
+15
Sentiment, −100 to +100
Medical Devices Market (2026)
$580.79B
Medical Devices Market (2031)
$817.78B
Life Science Market (2026)
$123.41B
Key driverStrong medical devices and bioprocessing market growth projections offset by Intuitive Surgical's U.S. slowdown concerns
Daily briefHealthcare· Money365.Market AI ·

MedTech Growth Accelerates; ISRG Falls on U.S. Slowdown

Global medical devices market forecast rises to $818B by 2031; Intuitive Surgical drops 7% after Q3 miss on domestic weakness

Medical Devices Market Outlook

Bullish
JNJABTPFE
01JNJ
Johnson & Johnson ($JNJ), Medtronic, Abbott ($ABT), and Siemens Healthineers are positioned among 25 companies profiled in a new market forecast projecting the global medical devices market will grow from $580.79 billion in 2026 to $817.78 billion by 2031. The expansion reflects rising chronic disease prevalence, increased hospital investment, and aging populations, though lengthy approval processes and staff shortages present headwinds.
02
The global life science market is projected to increase from $109.53 billion in 2025 to $123.41 billion in 2026, driven by rising pharmaceutical research and development investment, biotechnology innovation, laboratory automation, and growing demand for advanced diagnostics.
03PFE
Roche, Pfizer ($PFE), and AstraZeneca are among companies positioned to capture opportunities in AI and precision medicine applications.

Bioprocessing Equipment & Reagents Expansion

Bullish

Bioprocessing Reagent Market CAGR

12.3%

Cell Culture Media Market (2030)

$8.34B

Cell Culture Media CAGR

13.6%

Upstream Equipment Market (2026)

$12.32B
TMOMRK
01TMO
Thermo Fisher Scientific ($TMO), Danaher, Merck KGaA ($MRK), and Sartorius are accelerating adoption of AI optimization and single-use systems in the bioprocessing reagent market, which is expanding at a 12.3% compound annual growth rate. Single-use systems reduce contamination, downtime, and capital costs while improving yield, scalability, and efficiency for biologics manufacturers.
02
The global cell culture media and single-use reagents market is poised to reach $8.34 billion by 2030, expanding at a 13.6% CAGR as integrated single-use bioreactors reduce contamination, setup time, cleaning requirements, footprint, and operating costs.
03TMO
Lonza joins Thermo Fisher Scientific ($TMO), Merck ($MRK), and Sartorius in capturing market share driven by rising biopharmaceutical production demand.
04
The upstream bioprocessing equipment market is projected to grow from $11.13 billion in 2025 to $12.32 billion in 2026, representing a 10.9% CAGR, as biopharmaceutical manufacturers expand production capacity and adopt more flexible manufacturing technologies.
05TMO
Repligen joins Thermo Fisher Scientific ($TMO), Danaher, and Sartorius in driving single-use scale-up solutions.
06
The global bioprocessing support services market is experiencing rapid expansion driven by increasing biopharmaceutical production and greater outsourcing of development and manufacturing, with the market projected to reach $4.13 billion by 2030.
07TMO
Samsung Biologics joins Thermo Fisher Scientific ($TMO), Merck ($MRK), and Sartorius in scaling single-use integrated platforms that standardize scale-up, optimization, and compliance.

Surgical Robotics & Devices

Bearish

ISRG After-Hours Decline

7%-7%

ISRG Q3 Revenue

$3B+22%

ISRG Recurring Revenue

84%
01ISRG
Intuitive Surgical ($ISRG) shares fell approximately 7% in after-hours trading after the company reported third-quarter 2026 revenue growth of 22% to just over $3 billion, as U.S. market conditions showed the lowest growth levels since COVID-19. The company said 84% of quarterly revenue was recurring revenue, while procedure growth, system placements, and adoption of newer platforms supported results, though shares traded to about $406 on investor concerns about domestic market dynamics.
02TMO
Thermo Fisher Scientific ($TMO) posted Q3 2026 results with adjusted earnings per share beating consensus expectations and revenue in line with forecasts, supported by margin expansion and strong free cash flow that delivered a solid operating quarter for the life science tools provider.

Big Pharma Pipeline & Strategy

Neutral

MRK One-Year Return

76.2%+76.2%

S&P 500 One-Year Return

17.4%+17.4%

PFE Dividend Yield

5.8%

ABBV Annual Free Cash Flow

$17.8B
MRKPFELLYABBV
01
Moderna is transitioning focus toward cancer therapeutics as its coronavirus vaccine business matures, with the strategic pivot drawing increased Wall Street attention to its oncology pipeline and mRNA platform applications beyond infectious disease.
02MRK▲ +3.25%
Merck & Co ($MRK) shares returned 76.2% over the past year, compared with 17.4% for the S&P 500, though U.S. growth for the company's cancer drug Keytruda is set to slow as the drug reaches peak penetration across several key indications. A Dutch court barred Merck ($MRK) from selling subcutaneous Keytruda in eight European markets, adding regulatory complexity to the company's blockbuster oncology franchise.
03PFE
Pfizer ($PFE) stock yielded 5.8% at the October 19, 2026 close, though the share price has fallen behind the S&P 500 over the past five years despite dividend distributions to holders of the maker of medicines including Eliquis and Padcev.
04LLY▲ +3.49%
Novo Nordisk is pressing ahead with obesity and cardiometabolic drug development, including CagriSema regulatory submissions and a partnership with Prothena on Coramitug, while running a DKK 15 billion share buyback that has added to its treasury share position since February 2026. Growing competition from Eli Lilly ($LLY) and Viking Therapeutics, together with U.S. scrutiny of GLP-1 linked supplement use, highlights both the strength of the company's core obesity franchise and regulatory challenges.
05ABBV
AbbVie ($ABBV) generates $17.8 billion in annual free cash flow but faces patent cliff challenges, while Vertex Pharmaceuticals ($VRTX) boasts a 33% net margin with concentrated cystic fibrosis exposure as the company shifts strategic priorities beyond its CF franchise toward sustained growth in newer therapeutic areas.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy